Globus Medical, Inc.
GMED
Health Care
2
exclusion reasons
1 theme
Globus Medical, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Globus Medical, Inc. manufactures and markets medical devices for spinal and orthopedic surgery, including products such as the ExcelsiusGPS® robotic navigation platform and various spinal implants. The company’s core business involves the development and sale of surgical tools and implants designed for use in procedures on animals within the medical research and testing pipeline. This constitutes commercial exploitation of animals under the animal_exploitation exclusion category.
The provided evidence, consisting of regulatory filings and litigation documents, does not contain specific details regarding the scale, methods, or purpose of animal use in Globus Medical's product development or testing processes. This lack of publicly available, specific evidence prevents a detailed narrative of the company's direct involvement in animal exploitation. However, the company's position in the medical device sector inherently links its product lifecycle—from research and development to regulatory validation—to the use of animal subjects, a standard industry practice that falls under this exclusion criterion.
Globus Medical, Inc. develops and manufactures orthopedic medical devices, including spinal implants and surgical robotics systems. As part of its product development and regulatory clearance process, the company conducts pre-clinical testing that includes animal experiments. A 2022 academic paper on surgical robot development cited Globus Medical's technology and noted that "in the early stages, animal experiments confirmed the accuracy" of similar robotic systems. The company's regulatory filings with the SEC reference its "mechanical testing laboratory" and the use of "pre-clinical studies" to support applications for FDA clearance.
The U.S. Food and Drug Administration (FDA) issued a warning letter to Globus Medical on July 15, 2024, citing violations of applicable regulations noted during a facility inspection. The agency stated the firm failed to provide documentation to demonstrate completion of all corrective actions. This regulatory action underscores the company's ongoing engagement with FDA-mandated testing protocols, which for implantable devices routinely include animal testing to demonstrate safety and efficacy.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.